Research progress on small molecule inhibitors of coronaviruses
10.12206/j.issn.1006-0111.202005020
- VernacularTitle:冠状病毒小分子抑制剂研究进展
- Author:
Zhengguang YAO
1
,
2
;
Zhibin WANG
2
;
Chunnian XIA
3
;
Chunlin ZHUANG
2
Author Information
1. School of Pharmacy, Zhejiang University of Technology, Hangzhou 310014, China
2. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
3. School of Pharmacy, Zhejiang University of Technology, Hangzhou 310014, China.
- Keywords:
coronavirus;
SARS-CoV;
MERS-CoV;
SARS-CoV-2;
targets;
inhibitors
- From:
Journal of Pharmaceutical Practice
2020;38(5):385-397
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus infection seriously threatens human health. There is no specific medication or vaccine so far. In recent years, domestic and foreign researchers have developed a variety of small-molecule inhibitors against the ligand S protein, RdRp, PLpro and 3CLpro of three highly pathogenic coronavirus, SARS-CoV，MERS-CoV，SARS-CoV-2. This article reviews the characteristics of these coronaviruses, action targets, small molecule inhibitors, and structure-activity relationships.
